Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Safety of paclitaxel-coated devices in peripheral artery disease

Although an unplanned, interim analysis from an ongoing randomized trial in Sweden has suggested no significant difference in mortality between patients with peripheral artery disease receiving paclitaxel-coated devices and those receiving uncoated devices for lower-extremity revascularization, the analysis did not resolve the question of whether paclitaxel-coated devices are safe for these patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Schramm, K. M. et al. Recent trends in clinical setting and provider specialty for endovascular peripheral artery disease interventions for the Medicare population. J. Vasc. Interv. Radiol. 31, 614–621 (2020).

    Article  Google Scholar 

  2. Lindquist, J. & Shramm, K. Drug-eluting balloons and drug-eluting stents in the treatment of peripheral vascular disease. Semin. Intervent. Radiol. 35, 443–452 (2018).

    Article  Google Scholar 

  3. Ng, V. G., Mena, C., Pietras, C. & Lansky, A. J. Local delivery of paclitaxel in the treatment of peripheral artery disease. Eur. J. Clin. Invest. 45, 333–345 (2015).

    CAS  Article  Google Scholar 

  4. Rosenfield, K. et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N. Engl. J. Med. 373, 145–153 (2015).

    CAS  Article  Google Scholar 

  5. Dake, M. D. et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation 133, 1472–1483 (2016).

    CAS  Article  Google Scholar 

  6. Katsanos, K., Spiliopoulos, S., Kitrou, P., Krokidis, M. & Karnabatidis, D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J. Am. Heart Assoc. 7, e011245 (2018).

    Article  Google Scholar 

  7. Dan, K. et al. Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: insights from the Food and Drug Administration 2019 Circulatory System Devices Panel meeting on late mortality. Am. Heart J. 222, 112–120 (2020).

    CAS  Article  Google Scholar 

  8. Nordanstig, J. et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N. Engl. J. Med. 383, 2538–2546 (2020).

    CAS  Article  Google Scholar 

  9. Stone, G. W. et al. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS clinical trial program. JACC Cardiovasc. Interv. 4, 530–542 (2011).

    Article  Google Scholar 

  10. Wang, J., Lou, P., Lesniewski, R. & Henkin, J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14, 13–19 (2003).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Mary M. McDermott.

Ethics declarations

Competing interests

M.M.M. has received research funding from Regeneron and other research support from ArtAssist, Chromadex, Helixmith, Mars and ReserveAge. M.R.K. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

McDermott, M.M., Kibbe, M.R. Safety of paclitaxel-coated devices in peripheral artery disease. Nat Rev Cardiol 18, 311–312 (2021).

Download citation

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing